Targeting glucose metabolism in cancer: new class of agents for loco-regional and systemic therapy of liver cancer and beyond?

IF 1.2 Q4 ONCOLOGY

Hepatic Oncology Pub Date : 2016-01-01 DOI:10.2217/HEP.15.36

L. Savic, J. Chapiro, G. Duwe, J. Geschwind

引用次数: 21

Abstract

Hepatocellular carcinoma (HCC) is one of the most prevalent cancers and the third leading cause of cancer-related deaths worldwide. In patients with unresectable disease, loco-regional catheter-based intra-arterial therapies (IAT) can achieve selective tumor control while minimizing systemic toxicity. As molecular features of tumor growth and microenvironment are better understood, new targets arise for selective anticancer therapy. Particularly, antiglycolytic drugs that exploit the hyperglycolytic cancer cell metabolism - also known as the 'Warburg effect' - have emerged as promising therapeutic options. Thus, future developments will combine the selective character of loco-regional drug delivery platforms with highly specific molecular targeted antiglycolytic agents. This review will exemplify literature on antiglycolytic approaches and particularly focus on intra-arterial delivery methods.

查看原文本刊更多论文

靶向糖代谢治疗癌症:肝癌局部、局部和全身治疗的新药物?

肝细胞癌(HCC)是最常见的癌症之一，也是全球癌症相关死亡的第三大原因。对于无法切除的疾病患者，局部区域导管动脉内治疗(IAT)可以实现选择性肿瘤控制，同时最小化全身毒性。随着对肿瘤生长和微环境的分子特征的进一步了解，选择性抗癌治疗出现了新的靶点。特别是，利用高糖酵解癌细胞代谢的抗糖酵解药物——也被称为“Warburg效应”——已经成为有希望的治疗选择。因此，未来的发展将结合局部区域药物递送平台的选择性和高度特异性的分子靶向抗糖酵解药物。本综述将列举有关抗糖酵解方法的文献，并特别关注动脉内给药方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hepatic Oncology ONCOLOGY-

CiteScore

0.40

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Primary liver cancer is the sixth most common cancer in the world, and the third most common cause of death from malignant disease. Traditionally more common in developing countries, hepatocellular carcinoma is becoming increasingly prevalent in the Western world, primarily due to an increase in hepatitis C virus infection. Emerging risk factors, such as non-alcoholic fatty liver disease and obesity are also of concern for the future. In addition, metastatic tumors of the liver are more common than primary disease. Some studies report hepatic metastases in as many as 40 to 50% of adult patients with extrahepatic primary tumors. Hepatic Oncology publishes original research studies and reviews addressing preventive, diagnostic and therapeutic approaches to all types of cancer of the liver, in both the adult and pediatric populations. The journal also highlights significant advances in basic and translational research, and places them in context for future therapy. Hepatic Oncology provides a forum to report and debate all aspects of cancer of the liver and bile ducts. The journal publishes original research studies, full reviews and commentaries, with all articles subject to independent review by a minimum of three independent experts. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.